Melanoma: immune checkpoint blockade story gets better

Lancet. 2014 Sep 20;384(9948):1078-9. doi: 10.1016/S0140-6736(14)61140-5. Epub 2014 Jul 15.

Authors

Shailender Bhatia¹, John A Thompson²

Affiliations

¹ Medical Oncology, University of Washington, Seattle, WA, USA; Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
² Medical Oncology, University of Washington, Seattle, WA, USA; Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. Electronic address: [email protected].

PMID: 25034863
DOI: 10.1016/S0140-6736(14)61140-5

No abstract available

Publication types

Kommentar

MeSH terms

Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / administration & dosage*
Female
Humans
Male
Melanoma / drug therapy*
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Skin Neoplasms / drug therapy*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Programmed Cell Death 1 Receptor
pembrolizumab